This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia

This study has been completed.
Sponsor:
Information provided by:
Solstice Neurosciences
ClinicalTrials.gov Identifier:
NCT00702754
First received: June 12, 2008
Last updated: September 22, 2009
Last verified: September 2009
  Purpose
Five hundred patients with a confirmed clinical diagnosis of Cervical Dystonia (CD)are planned for enrollment into this open label study. These patients will be Type B toxin naive patients with CD. During this study patients will receive repeat injections of MYOBLOC when deemed appropriate by the Investigator. However, it will be recommended that injections occur not more frequently than every 12 weeks. Total duration of exposure to MYOBLOC will be targeted for at least two years, with potential exposure for up to 7 years in patients with earliest enrollment

Condition Intervention Phase
Cervical Dystonia Biological: Botulinum Toxin Type B Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia

Resource links provided by NLM:


Further study details as provided by Solstice Neurosciences:

Primary Outcome Measures:
  • Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms [ Time Frame: Session 1 - Time 0, 4 weeks post-injection compared to baseline ]

Secondary Outcome Measures:
  • Treatment Assessment Scale (TAS), Approx Wk 12 + 4 Wks Post-Injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 2 (12 wks) - 4 weeks post-injection compared to baseline ]
  • Treatment Assessment Scale (TAS), Approx Wk 24 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 3 (24 Wks) - 4 weeks post-injection compared to baseline ]
  • Treatment Assessment Scale (TAS), Approx Wk 36 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 4 (36 Wks) - 4 weeks post-injection compared to baseline ]
  • Treatment Assessment Scale (TAS), Approx Wk 48 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 5 (48 Wks) - 4 weeks post-injection compared to baseline ]
  • Treatment Assessment Scale (TAS), Approx Wk 60 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 6 (60 Wks) - 4 weeks post-injection compared to baseline ]
  • Treatment Assessment Scale (TAS), Approx Wk 72 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 7 (72 Wks) - 4 weeks post-injection compared to baseline ]
  • Treatment Assessment Scale (TAS), Approx Wk 84 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms [ Time Frame: Session 8 (84 Wks) - 4 weeks post-injection compared to baseline ]

Enrollment: 502
Study Start Date: June 2001
Study Completion Date: September 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Botulinum Toxin Type B
    Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
    Other Name: MYOBLOC
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • body weight of at least 46 kilograms
  • History of Cervical Dystonia of at least one year's duration who in the opinion of the Investigator requires treatment

Exclusion Criteria:

  • Inability to give informed consent
  • Patient who has been previously treated with botulinum Toxin Type B
  • Patient who has received a Botulinum toxin Type A injection in the last 12 weeks.
  • History of phenol injections involving the neck or shoulder region in the last 12 months.
  • Patients with neck contractures or cervical spine disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Sharon Reinhard, MS, Associate Director, Clinical Development, Solstice Neurosciences, Inc
ClinicalTrials.gov Identifier: NCT00702754     History of Changes
Other Study ID Numbers: 401CDNA
Study First Received: June 12, 2008
Results First Received: May 12, 2009
Last Updated: September 22, 2009

Additional relevant MeSH terms:
Dystonia
Dystonic Disorders
Torticollis
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases
rimabotulinumtoxinB
Botulinum Toxins, Type A
abobotulinumtoxinA
onabotulinumtoxinA
incobotulinumtoxinA
Botulinum Toxins
Anti-Dyskinesia Agents
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on June 23, 2017